Cargando…

Identification and Validation of Ferroptosis-Related LncRNAs Signature as a Novel Prognostic Model for Chronic Lymphocytic Leukemia

BACKGROUND: Chronic lymphocytic leukemia (CLL) is a subtype of B-cell malignancy with high heterogeneity. Ferroptosis is a novel cell death induced by iron and lipid peroxidation and exhibits prognostic value in many cancers. Emerging studies on long non-coding RNAs (lncRNAs) and ferroptosis reveal...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Zhangdi, Pan, Bihui, Li, Yue, Xia, Yi, Liang, Jinhua, Kong, Yilin, Zhang, Xinyu, Tang, Jing, Wang, Li, Li, Jianyong, Xu, Wei, Wu, Jiazhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149066/
https://www.ncbi.nlm.nih.gov/pubmed/37131869
http://dx.doi.org/10.2147/IJGM.S399629
_version_ 1785035094603333632
author Xu, Zhangdi
Pan, Bihui
Li, Yue
Xia, Yi
Liang, Jinhua
Kong, Yilin
Zhang, Xinyu
Tang, Jing
Wang, Li
Li, Jianyong
Xu, Wei
Wu, Jiazhu
author_facet Xu, Zhangdi
Pan, Bihui
Li, Yue
Xia, Yi
Liang, Jinhua
Kong, Yilin
Zhang, Xinyu
Tang, Jing
Wang, Li
Li, Jianyong
Xu, Wei
Wu, Jiazhu
author_sort Xu, Zhangdi
collection PubMed
description BACKGROUND: Chronic lymphocytic leukemia (CLL) is a subtype of B-cell malignancy with high heterogeneity. Ferroptosis is a novel cell death induced by iron and lipid peroxidation and exhibits prognostic value in many cancers. Emerging studies on long non-coding RNAs (lncRNAs) and ferroptosis reveal the unique value in tumorigenesis. However, the prognostic value of ferroptosis-related lncRNAs (FRLs) remains unclear in CLL. AIM: We aimed to construct a FRLs risk model to predict prognosis and improve prognostic stratification for clinical practice. METHODS: RNA-sequencing data and clinical characteristics of CLL patients were downloaded from the GEO database. Based on ferroptosis-related genes from FerrDb database, differentially expressed FRLs with prognostic significance were identified and used to generate the risk model. The capability of the risk model was assessed and evaluated. GO and KEGG analyses were performed to confirm biological roles and potential pathways. RESULTS: A novel ferroptosis-related lncRNAs prognostic score (FPS) model containing six FRLs (PRKCQ, TRG.AS1, LNC00467, LNC01096, PCAT6 and SBF2.AS1) was identified. Patients in the training and validation cohort were evenly divided into high- and low-risk groups. Our results indicated that patients in the high-risk group had worse survival than those in the low-risk group. Functional enrichment analyses showed that the differently expressed genes (DEGs) between the two groups were enriched in the chemokine signaling pathway, hematopoietic cell lineage, T cell differentiation, TCR pathway and NF-κB pathway. Moreover, significant differences in immune cell infiltration were also observed. Surprisingly, FPS was proved to be an independent prognostic indicator for OS. CONCLUSION: We established and evaluated a novel prognostic risk model with 6 FRLs that could predict prognosis accurately and describe the distinct immune infiltration in CLL.
format Online
Article
Text
id pubmed-10149066
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-101490662023-05-01 Identification and Validation of Ferroptosis-Related LncRNAs Signature as a Novel Prognostic Model for Chronic Lymphocytic Leukemia Xu, Zhangdi Pan, Bihui Li, Yue Xia, Yi Liang, Jinhua Kong, Yilin Zhang, Xinyu Tang, Jing Wang, Li Li, Jianyong Xu, Wei Wu, Jiazhu Int J Gen Med Original Research BACKGROUND: Chronic lymphocytic leukemia (CLL) is a subtype of B-cell malignancy with high heterogeneity. Ferroptosis is a novel cell death induced by iron and lipid peroxidation and exhibits prognostic value in many cancers. Emerging studies on long non-coding RNAs (lncRNAs) and ferroptosis reveal the unique value in tumorigenesis. However, the prognostic value of ferroptosis-related lncRNAs (FRLs) remains unclear in CLL. AIM: We aimed to construct a FRLs risk model to predict prognosis and improve prognostic stratification for clinical practice. METHODS: RNA-sequencing data and clinical characteristics of CLL patients were downloaded from the GEO database. Based on ferroptosis-related genes from FerrDb database, differentially expressed FRLs with prognostic significance were identified and used to generate the risk model. The capability of the risk model was assessed and evaluated. GO and KEGG analyses were performed to confirm biological roles and potential pathways. RESULTS: A novel ferroptosis-related lncRNAs prognostic score (FPS) model containing six FRLs (PRKCQ, TRG.AS1, LNC00467, LNC01096, PCAT6 and SBF2.AS1) was identified. Patients in the training and validation cohort were evenly divided into high- and low-risk groups. Our results indicated that patients in the high-risk group had worse survival than those in the low-risk group. Functional enrichment analyses showed that the differently expressed genes (DEGs) between the two groups were enriched in the chemokine signaling pathway, hematopoietic cell lineage, T cell differentiation, TCR pathway and NF-κB pathway. Moreover, significant differences in immune cell infiltration were also observed. Surprisingly, FPS was proved to be an independent prognostic indicator for OS. CONCLUSION: We established and evaluated a novel prognostic risk model with 6 FRLs that could predict prognosis accurately and describe the distinct immune infiltration in CLL. Dove 2023-04-26 /pmc/articles/PMC10149066/ /pubmed/37131869 http://dx.doi.org/10.2147/IJGM.S399629 Text en © 2023 Xu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Xu, Zhangdi
Pan, Bihui
Li, Yue
Xia, Yi
Liang, Jinhua
Kong, Yilin
Zhang, Xinyu
Tang, Jing
Wang, Li
Li, Jianyong
Xu, Wei
Wu, Jiazhu
Identification and Validation of Ferroptosis-Related LncRNAs Signature as a Novel Prognostic Model for Chronic Lymphocytic Leukemia
title Identification and Validation of Ferroptosis-Related LncRNAs Signature as a Novel Prognostic Model for Chronic Lymphocytic Leukemia
title_full Identification and Validation of Ferroptosis-Related LncRNAs Signature as a Novel Prognostic Model for Chronic Lymphocytic Leukemia
title_fullStr Identification and Validation of Ferroptosis-Related LncRNAs Signature as a Novel Prognostic Model for Chronic Lymphocytic Leukemia
title_full_unstemmed Identification and Validation of Ferroptosis-Related LncRNAs Signature as a Novel Prognostic Model for Chronic Lymphocytic Leukemia
title_short Identification and Validation of Ferroptosis-Related LncRNAs Signature as a Novel Prognostic Model for Chronic Lymphocytic Leukemia
title_sort identification and validation of ferroptosis-related lncrnas signature as a novel prognostic model for chronic lymphocytic leukemia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149066/
https://www.ncbi.nlm.nih.gov/pubmed/37131869
http://dx.doi.org/10.2147/IJGM.S399629
work_keys_str_mv AT xuzhangdi identificationandvalidationofferroptosisrelatedlncrnassignatureasanovelprognosticmodelforchroniclymphocyticleukemia
AT panbihui identificationandvalidationofferroptosisrelatedlncrnassignatureasanovelprognosticmodelforchroniclymphocyticleukemia
AT liyue identificationandvalidationofferroptosisrelatedlncrnassignatureasanovelprognosticmodelforchroniclymphocyticleukemia
AT xiayi identificationandvalidationofferroptosisrelatedlncrnassignatureasanovelprognosticmodelforchroniclymphocyticleukemia
AT liangjinhua identificationandvalidationofferroptosisrelatedlncrnassignatureasanovelprognosticmodelforchroniclymphocyticleukemia
AT kongyilin identificationandvalidationofferroptosisrelatedlncrnassignatureasanovelprognosticmodelforchroniclymphocyticleukemia
AT zhangxinyu identificationandvalidationofferroptosisrelatedlncrnassignatureasanovelprognosticmodelforchroniclymphocyticleukemia
AT tangjing identificationandvalidationofferroptosisrelatedlncrnassignatureasanovelprognosticmodelforchroniclymphocyticleukemia
AT wangli identificationandvalidationofferroptosisrelatedlncrnassignatureasanovelprognosticmodelforchroniclymphocyticleukemia
AT lijianyong identificationandvalidationofferroptosisrelatedlncrnassignatureasanovelprognosticmodelforchroniclymphocyticleukemia
AT xuwei identificationandvalidationofferroptosisrelatedlncrnassignatureasanovelprognosticmodelforchroniclymphocyticleukemia
AT wujiazhu identificationandvalidationofferroptosisrelatedlncrnassignatureasanovelprognosticmodelforchroniclymphocyticleukemia